BROOKLYN, N.Y.--(BUSINESS WIRE)-- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or the Company), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer... More